Want to see PSTV full AI Analyst Report?
PSTV Stock Chart & Stats
$3.83
-$0.02(-0.52%)
At close: 4:00 PM EDT
$3.83
-$0.02(-0.52%)
Day’s Range― - ―
52-Week Range$2.90 - $23.44
Previous CloseN/A
Volume34.82K
Average Volume (3M)191.43K
Market Cap
$26.64M
Enterprise Value$12.63
Total Cash (Recent Filing)$3.02M
Total Debt (Recent Filing)$725.00K
Price to Earnings (P/E)―
Beta1.43
Next Earnings
Aug 19, 2026EPS Estimate
-0.88Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-417.08
Shares Outstanding6,883,106
10 Day Avg. Volume153,178
30 Day Avg. Volume191,434
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)9.98
Price to Sales (P/S)7.65
P/FCF Ratio-1.91
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$39.67Price Target Upside935.68% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-3.98
Revenue Forecast (FY)$6.24M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained very high gross margins indicate the company’s radiotherapeutic products have favorable unit economics. If clinical programs advance and sales scale, these margins support durable operating leverage and potential profitability despite current fixed R&D costs.
Regulatory Exclusivity & GovernanceOrphan Drug Designation provides regulatory and commercial advantages (e.g., potential market exclusivity and development incentives). Restored listing and strengthened leadership improve governance and lower execution risk for multi-year clinical programs and partner discussions.
Low Financial LeverageModest debt levels reduce near-term solvency pressure and interest burden, giving the company flexibility to prioritize R&D spending and manage clinical programs. Low leverage supports resilience during extended development timelines.
Bears Say
Negative Cash Flow / High BurnPersistent, substantial cash burn relative to company scale creates structural funding risk. Continued negative operating and free cash flow means the company must secure external capital to sustain trials, which can delay programs or force unfavorable financing terms.
Very Small, Declining Revenue And Deep LossesA tiny and shrinking revenue base combined with extremely negative net margins indicates operations are not yet supporting fixed costs. This weak earnings profile limits internal reinvestment capacity and heightens dependence on external funding and milestone-driven partner deals.
Reliance On Equity Financing (Dilution Risk)An at-the-market equity program provides flexible liquidity but signals ongoing reliance on share issuance to fund operations. Repeated equity raises dilute existing holders and can constrain long-term shareholder alignment and reduce financial predictability for multi-year development.
Plus Therapeutics News
PSTV FAQ
What was Plus Therapeutics’s price range in the past 12 months?
Plus Therapeutics lowest stock price was $2.90 and its highest was $23.44 in the past 12 months.
What is Plus Therapeutics’s market cap?
Plus Therapeutics’s market cap is $26.64M.
When is Plus Therapeutics’s upcoming earnings report date?
Plus Therapeutics’s upcoming earnings report date is Aug 19, 2026 which is in 17 days.
How were Plus Therapeutics’s earnings last quarter?
Plus Therapeutics released its earnings results on Apr 16, 2026. The company reported -$1.05 earnings per share for the quarter, missing the consensus estimate of -$0.848 by -$0.202.
Is Plus Therapeutics overvalued?
According to Wall Street analysts Plus Therapeutics’s price is currently Undervalued.
Does Plus Therapeutics pay dividends?
Plus Therapeutics does not currently pay dividends.
What is Plus Therapeutics’s EPS estimate?
Plus Therapeutics’s EPS estimate is -0.88.
How many shares outstanding does Plus Therapeutics have?
Plus Therapeutics has 6,883,106 shares outstanding.
What happened to Plus Therapeutics’s price movement after its last earnings report?
Plus Therapeutics reported an EPS of -$1.05 in its last earnings report, missing expectations of -$0.848. Following the earnings report the stock price went up 5.31%.
Which hedge fund is a major shareholder of Plus Therapeutics?
Currently, no hedge funds are holding shares in PSTV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Plus Therapeutics
Plus Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, dedicated to the development, manufacturing, and market introduction of therapeutic solutions for cancer patients and individuals with other serious illnesses. A cornerstone of their pipeline is Rhenium-186 NanoLiposome (R-186 NL), a patented radiotherapy specifically engineered to address difficult central nervous system (CNS) cancers, such as recurrent glioblastoma, leptomeningeal metastases, and various brain cancers affecting children. The company has also secured a licensing agreement with NanoTx, Corp. to advance and commercialize NanoTx's treatment for glioblastoma. Founded in 1996 and headquartered in Austin, Texas, the firm adopted its current name, Plus Therapeutics, Inc., in July 2019, having previously operated as Cytori Therapeutics, Inc.
PSTV Stock 12 Month Forecast
Average Price Target
$39.67
▲(935.68% Upside)
Technical Analysis
Karyopharm Therapeutics
―
Tvardi Therapeutics
―
Barinthus Biotherapeutics
―
Senti Biosciences
―
Acrivon Therapeutics, Inc.
―
Ownership Overview
2.91% Insiders
<0.01% Other Institutional Investors
92.32% Public Companies and
Individual Investors